The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

NCT01460069 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1, which is normally used for diabetes, can help reduce symptoms of psoriasis in adults with the condition.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2011-10 · est. completion 2013-05

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01460069 ↗

Description as written by the study sponsor.

The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on psoriasis in a double-blinded, randomized placebo-controlled clinical trial.

Treatments tested

liraglutide Drug

Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
Placebo Drug

The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.

Main thing measured	PASI (psoriasis area and severity index)
Sponsor	Annesofie Faurschou
Conditions studied	Psoriasis
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01460069 ↗